TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Myelodysplastic syndromes (MDS) require accurate risk stratification for patient care.
• Complex karyotype (CK), defined as >2 cytogenetic abnormalities, is a poor prognostic marker in MDS.
• CK-MDS patients exhibit diverse chromosomal abnormalities and somatic mutations, necessitating refined prognostic models.

Purpose of the Study:

• To refine risk stratification for patients with complex karyotype myelodysplastic syndromes (CK-MDS).
• To investigate the impact of specific chromosomal abnormalities and somatic mutations on survival in CK-MDS.
• To identify key factors for improved prognostic accuracy in CK-MDS.

Main Methods:

• Analysis of data from 359 CK-MDS patients.
• Examination of chromosomal abnormalities and somatic mutations, with a focus on TP53.
• Multivariable survival modeling incorporating clinical and cytogenetic features.

Main Results:

• TP53 mutations were present in 55% of CK-MDS patients.
• TP53-mutated patients showed enrichment for del(5q), monosomal karyotype, and high complexity (>4 abnormalities).
• Multivariable analysis identified severe anemia, NRAS, SF3B1, TP53 mutations, elevated blasts, abnormal 3q, abnormal 9, and monosomy 7 as significant survival risks.

Conclusions:

• The poor prognosis of CK-MDS is significantly influenced by TP53 mutations.
• Integrating clinical and karyotype features, particularly TP53 status, refines risk stratification for CK-MDS patients.
• Accurate prognostic models are crucial for managing CK-MDS and guiding treatment decisions.